Iovance Biotherapeutics, Inc. - Common Stock (IOVA)
1.9700
-0.1400 (-6.64%)
NASDAQ · Last Trade: Aug 11th, 7:37 PM EDT
Detailed Quote
Previous Close
2.110
Open
2.140
Bid
1.960
Ask
1.970
Day's Range
1.950 - 2.200
52 Week Range
1.639 - 12.51
Volume
15,407,236
Market Cap
601.35M
PE Ratio (TTM)
-1.615
EPS (TTM)
-1.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
26,569,470
Chart
About Iovance Biotherapeutics, Inc. - Common Stock (IOVA)
Iovance Biotherapeutics is a clinical-stage biotechnology company focused on the development and commercialization of novel cell therapy products for the treatment of cancer. The company specializes in the use of tumor-infiltrating lymphocyte (TIL) therapy, which harnesses the body’s immune system to target and destroy cancer cells. By processing and expanding patients' own immune cells, Iovance aims to create personalized therapies that can provide effective options for those with various types of solid tumors. Their innovative approach leverages advancements in cell therapy to improve patient outcomes and contribute to the evolving landscape of cancer treatment. Read More
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2025 financial results and corporate updates on Thursday, August 7, 2025.
Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.
Health In Tech (NASDAQ: HIT), a fast-growing Insurtech platform powered by third-party AI technology, announced second quarter financial results that underscored explosive growth and strong fundamentals, positioning the company as a standout in the digital health insurance sector.
